Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Roche will pay Oryzon Genomics up to $21 million in up-front and near-term payments as part of a pact to develop drugs that block lysine-specific demethylase-1 (LSD1), an epigenetic target that regulates gene expression. Under the deal, Roche will take the reins in further developing the Spanish firm’s lead molecule, ORY-1001, which is in Phase I/IIa studies as a treatment for acute myeloid leukemia. Roche also gains the rights to two patent families related to LSD1. The companies will work together to better understand how LSD1 inhibitors can be used to treat cancer.
This article has been sent to the following recipient: